Synonyms: bimekizumab-bkzx | Bimzelx® | CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
bimekizumab is an approved drug (EMA (2021), FDA (2023))
Compound class:
Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized monoclonal antibody that simultaneously targets IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis were reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].
|
Bioactivity Comments |
Binds to human recombinant IL-17A/F heterodimer with a Kd of 0.116nM, and monkey (cynomolgus) IL-17F with Kd of ~1nM [1]. |
Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|